New antibody drug targets Hard-to-Treat cancers in first human trial

NCT ID NCT06636435

First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 25 times

Summary

This early-phase study tests a new drug called CBA-1205, an antibody that targets a protein (DLK1) found on some cancer cells. The main goal is to check safety and find the right dose in about 66 adults with advanced solid tumors, including liver cancer and melanoma. Participants receive the drug and are monitored for side effects and how their body processes it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Kanagawa Cancer Center

    RECRUITING

    Yokohama, Kanagawa, 241-8515, Japan

  • National Cancer Center Hospital

    RECRUITING

    Chūō, Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East

    RECRUITING

    Kashiwa, Chiba, 277-8577, Japan

  • Niigata University Medical and Dental Hospital

    RECRUITING

    Niigata, Niigata, 951-8520, Japan

  • University of Yamanashi Hospital

    RECRUITING

    Chūō, Yamanashi, 409-3898, Japan

Conditions

Explore the condition pages connected to this study.